Sateesh Nagumantry

Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapy

Jad Othman, Ing Soo Tiong, Jenny O’Nions et al. · Blood · 2023 · 65 citations · Full text

Medicine, Hematology, Oncology +14

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard Kelly, Matthew T. Holt, Jennifer Vidler et al. · Blood · 2023 · 47 citations

Life Sciences, Immunology, Pharmacology +5

Real‐world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria

Morag Griffin, Richard Kelly, Isabelle Brindel et al. · American Journal of Hematology · 2024 · 39 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential

Chunye Zhang, Ellen Stelloo, Sharon Barrans et al. · Leukemia · 2024 · 26 citations · Full text

Life Sciences, Hematology, Oncology +13

<scp>CREST</scp>‐<scp>UK</scp>: Real‐world effectiveness, safety and outpatient delivery of <scp>CPX</scp>‐351 for first‐line treatment of newly diagnosed therapy‐related <scp>AML</scp> and <scp>AML</scp> with myelodysplasia‐related changes in the <scp>UK</scp>

Priyanka Mehta, Victoria Campbell, Jamie Maddox et al. · British Journal of Haematology · 2024 · 14 citations · Full text

Medicine, Hematology, Pharmacology +13